YLT192, a Novel, Orally Active Bioavailable Inhibitor of VEGFR2 Signaling with Potent Antiangiogenic Activity and Antitumor Efficacy in Preclinical Models

Antagonizing vascular endothelial growth factor receptor 2 (VEGFR2) to block angiogenesis has been applied toward cancer therapy for its role in promoting cancer growth and metastasis. However, most these clinical anticancer drugs have unexpected side effects. Development of novel VEGFR2 inhibitors...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Yong, Song, Xuejiao, Li, Deliang, Ye, Tinghong, Xu, Youzhi, Lin, Hongjun, Meng, Nana, Li, Guobo, Deng, Senyi, Zhang, Shuang, Liu, Li, Zhu, Yongxia, Zeng, Jun, Lei, Qian, Pan, Youli, Wei, Yuquan, Zhao, Yinglan, Yu, Luoting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4129416/
https://www.ncbi.nlm.nih.gov/pubmed/25112436
http://dx.doi.org/10.1038/srep06031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4129416/
https://www.ncbi.nlm.nih.gov/pubmed/25112436
http://dx.doi.org/10.1038/srep06031

Ejemplares similares